Featured Research

from universities, journals, and other organizations

FDA considers new rules to speed up confirmatory trials of drugs granted accelerated approval

Date:
March 25, 2011
Source:
Journal of the National Cancer Institute
Summary:
Since 1992, the US Food and Drug Administration has granted accelerated approval to 47 new indications for 35 cancer drugs and in more than half the cases -- 26 indications -- further trials have confirmed the benefits of the drugs. But the agency has concerns about the length of time some drugs have remained on the market without confirmation of their benefits, according to a review article.

Since 1992, the U.S. Food and Drug Administration has granted accelerated approval to 47 new indications for 35 cancer drugs and in more than half the cases -- 26 indications -- further trials have confirmed the benefits of the drugs. But the agency has concerns about the length of time some drugs have remained on the market without confirmation of their benefits, according to a review article published online March 25 in the Journal of the National Cancer Institute.

Related Articles


New requirements and fines are possible solutions say the authors, from FDA's Office of Oncology Drug Products.

John R. Johnson, M.D., and colleagues reviewed the FDA's experience with the accelerated approval process from its beginning in 1992 to July 2010. Among the 26 indications that eventually received regular approval, the median time between accelerated approval and regular approval was 3.9 years and the average time was 4.7 years. These represent "substantial time savings in terms of earlier availability of drugs to patients," the authors write.

However, three indications have been withdrawn from the market or placed under very restricted patient distribution because subsequent trials did not confirm a benefit. Two were on the market for 10 years before being withdrawn. Fourteen accelerated approvals still do not have completed confirmatory trials; one of these drugs has been on the market for 10.5 years, and three have been marketed for more than 5 years. And among the indications that have converted from accelerated approval to regular approval, five took longer than 7 years to complete confirmatory trials, with one taking 12.6 years and another 9.7 years.

"Because of the possibility that confirmatory trials will not confirm clinical benefit, indications that have received accelerated approval should not be on the market for unacceptably prolonged intervals in the absence of completed confirmatory trials," the authors write.

They suggest that one solution to this problem is for the FDA to require that a confirmatory trial be in progress before granting accelerated approval. Another is to make use of the Food, Drug and Cosmetic Act of 2007, which gave the FDA authority to fine companies up to $10 million for lack of due diligence in completing confirmatory trials. "The FDA believes that this will be an effective new tool," the authors conclude.

In an accompanying editorial, Susan S. Ellenberg, Ph.D., of the University of Pennsylvania School of Medicine in Philadelphia, notes that analyses such as this one are essential in improving the regulatory process. She discusses several questions that are not fully addressed by the current review, the most important of which is the extent to which accelerated approval actually speeds the availability of products.

Ellenberg argues that the time to complete a study that was aimed at regular approval from the start would likely be shorter than the time to do first a study for accelerated approval and then a second, confirmatory study. "Thus the time to availability of a new drug, although undoubtedly shorter with accelerated approval as an option, may not be as impressive as Johnson et al. suggest."

The editorialist adds that the FDA's new regulatory science initiative announced last fall "should support more in-depth analyses of regulatory data that could provide valuable insights regarding optimization of regulatory approaches."


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal of the National Cancer Institute. "FDA considers new rules to speed up confirmatory trials of drugs granted accelerated approval." ScienceDaily. ScienceDaily, 25 March 2011. <www.sciencedaily.com/releases/2011/03/110325164214.htm>.
Journal of the National Cancer Institute. (2011, March 25). FDA considers new rules to speed up confirmatory trials of drugs granted accelerated approval. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2011/03/110325164214.htm
Journal of the National Cancer Institute. "FDA considers new rules to speed up confirmatory trials of drugs granted accelerated approval." ScienceDaily. www.sciencedaily.com/releases/2011/03/110325164214.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Science & Society News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Police Swoop on 80 Airports in Global Ticket Fraud Crackdown

Police Swoop on 80 Airports in Global Ticket Fraud Crackdown

AFP (Nov. 28, 2014) Police have arrested 118 people in an unprecedented globally-coordinated swoop on plane ticket credit card fraud, a billion-dollar organised crime industry, officials said Friday. Duration: 01:03 Video provided by AFP
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
EU Pushes Google For Worldwide Right To Be Forgotten

EU Pushes Google For Worldwide Right To Be Forgotten

Newsy (Nov. 27, 2014) Privacy regulators recommend Google expand its requested removals to apply to all its web domains. Video provided by Newsy
Powered by NewsLook.com
Who Will Failed Nuclear Talks Hurt Most?

Who Will Failed Nuclear Talks Hurt Most?

Reuters - Business Video Online (Nov. 25, 2014) With no immediate prospect of sanctions relief for Iran, and no solid progress in negotiations with the West over the country's nuclear programme, Ciara Lee asks why talks have still not produced results and what a resolution would mean for both parties. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Science & Society

Business & Industry

Education & Learning

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins